Skip to main content

news

Jones Day has advised Japan’s Astellas Pharma on its $5.9 billion acquisition of U.S. drugmaker Iveric Bio, which was represented by Skadden, Arps, Slate, Meagher & Flom and Wilmer Cutler Pickering Hale and Dorr.

This is the second-largest cross-border acquisition by a Japanese drugmaker in the past five years, following Takeda Pharmaceutical's $6 billion purchase of Nimbus Therapeutics' psoriasis drug unit that was announced last December, Reuters reported.

This acquisition, the largest for Astellas, is expected to give it access to a range of ophthalmology treatments, Reuters added.

Partner Jonn Beeson led the Jones Day team.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.

Wadia Ghandy, CAM guide StanChart’s $490 mln sale of personal loan business

by Nimitt Dixit |

Wadia Ghandy has guided Kotak Mahindra on its acquisition of Standard Chartered Bank’s personal loan business in India for $490 million, with Cyril Amarchand Mangaldas advising Standard Chartered.

AZB, S&R act on $645 mln Afcons IPO

by Nimitt Dixit |

AZB & Partners is advising Afcons, one of India’s largest international infrastructure construction companies, on its upcoming initial public offering worth $645 million. S&R Associates is acting for the bookrunning lead managers.